Skip to main content

Table 2 Baseline demographics and disease characteristics

From: Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain

Demographics and disease characteristics Analyzed patients (n = 495)
  EBRT (n = 361) BQT (n = 134)
Median age, years (range) 73.0 (48.0–84.0) 67.0 (48.0–82.0)
Gleason score (grouped),a n (%)   
 Grade group 1
 Grade group 2
 Grade group 3
 Grade group 4
 Grade group 5
97 (26.9)
94 (26.0)
74 (20.5)
55 (15.2)
41 (11.4)
113 (84.3)
21 (15.7)
0
0
0
Median prostate-specific antigen at diagnosis, ng/mL (range) 8.1 (1.7–342.0) 5.9 (1.0–15.7)
Median prostate-specific antigen at initial EBRT/BQT, ng/mL (range) 3.5 (.0–100.0) 5.8 (.8–17.2)
Median testosterone at initial EBRT/BQT, ng/dL (range) n = 177
10.0 (.0–913.0)
n = 21
291.0 (2.6–619.6)
TNM stage at initial EBRT/BQT, n (%)   
 T1c
 T2
 T3
104 (28.8)
148 (41.0)
68 (18.8)
91 (67.9)
19 (14.2)
0
Eastern Cooperative Oncology Group performance status at initial EBRT/BQT, n (%) n = 341 n = 130
 0
 1
 2
 Not available
314 (92.1)
23 (6.7)
4 (1.2)
20
125 (96.2)
5 (3.8)
0
4
Type of BQT, n (%)   
 Low-dose BQT/seed
 High-dose BQT
NA 118 (88.1)
16 (11.9)
Location of EBRT treatment, n (%)   
 Prostate
 Lymph nodes
 Seminal vesicles
361 (100)
94 (26.0)
280 (77.6)
NA
Type of EBRT treatment,b n (%)   
 3D CRT
 IMRT or VMAT
104 (29.1)
254 (70.9)
NA
Neo-adjuvant hormone treatment, n (%)   
 Prior to EBRT/BQT
 Initiating EBRT/BQT
224 (62.0)
219 (97.8)
5 (2.2)
8 (6.0)
8 (100.0)
Previous interventions, n (%)   
 Yes
 No
 Unknown
141 (39.1)
213 (59.0)
7 (1.9)
25 (18.7)
109 (81.3)
Previous surgery, n (%)   
 TURP 39 (10.8) 8 (6.0)
  1. aGrade group 1 = Gleason score ≤ 6; Grade group 2 = Gleason score 3 + 4 = 7; Grade group 3 = Gleason score 4 + 3 = 7; Grade group 4 = Gleason score 8; Grade group 5 = Gleason scores 9 and 10[28]
  2. bOf patients who received EBRT treatment of the prostate (n = 358)
  3. 3D CRT Three-dimensional conformal radiation therapy, IMRT Intensity-modulated radiation therapy, NA Not available, TNM Tumor, node, metastasis, TURP Transurethral resection of the prostate, VMAT Volumetric-modulated arc therapy